Research shows that PixCell’s HemoScreen™ can be used to monitor pathological blood samples and improve the treatment process of patients with blood diseases
ILIT, York, Israel, October 13, 2020 /PRNewswire/ – PixCell Medical, the innovator of rapid bedside diagnostic solutions, today announced the results of a new study published in the International Journal of Laboratory Hematology As a result, the study shows that the company’s HemoScreen™ bedside blood analyzer is suitable for the evaluation and management of blood cancer patients undergoing chemotherapy treatment.
Researchers from the North New Zealand Hospital, the University of Copenhagen, the Bispebjerg and Frederiksberg Hospitals in Copenhagen, and the University of Southern Denmark compared HemoScreen™ and Sysmex XN-9000 in 206 routine vein samples and 79 white blood cell (WBC) capillary bedside samples , Absolute neutrophil count (ANC), red blood cell (RBC), platelet count (PLT) and hemoglobin (HGB).
“Cancer patients undergoing intensive chemotherapy often suffer from severe bone marrow suppression due to treatment and require regular monitoring of complete blood counts (CBC),” said Dr. Avishay Bransky, CEO of PixCell Medical. “This study shows that HemoScreen can provide fast and reliable results for general samples and pathological samples. Widespread use of this device may eliminate irrelevant hospital visits and significantly shorten the necessary consultation time-for those who already suffer from illness and fatigue. For patients, this is a game changing game.”
The data shows that HemoScreen uses 40 μl of venous or capillary blood and low concentrations of WBC, ANC, RBC, PLT and HGB to provide fast and clinically reliable test results for guiding blood transfusion and post-chemotherapy treatment. The research team also found that HemoScreen is sufficiently sensitive to label pathological samples and abnormal cells (including nucleated red blood cells, immature granulocytes, and primitive cells), and greatly reduces the turnaround time of test results.
HemoScreen™, developed by PixCell Medical, is the only hematology analyzer approved by the FDA, designed for point-of-care (POC), combining flow cytometry and digital imaging on a single platform. The portable compact hematology analyzer can complete a complete blood count (CBC) test in 6 minutes, and uses a disposable disposable kit pre-filled with all necessary reagents for fast, accurate and simple laboratory tests.
The study concluded that HemoScreen is very suitable for smaller outpatient clinics and may be suitable for home use.
PixCell Medical provides the first truly portable instant blood diagnostic solution. Utilizing the company’s patented viscoelastic focusing technology and artificial intelligence machine vision, PixCell’s FDA-approved and CE-approved HemoScreen diagnostic platform reduces the delivery time of diagnostic results from a few days to a few minutes. With just a drop of blood, PixCell can provide accurate readings of 20 standard blood count parameters within six minutes, saving patients, clinicians and health systems a lot of time and cost.
Post time: Jul-15-2021